PLERIXAFOR

Post-LOE

plerixafor

Hetero

ANDASUBCUTANEOUSSOLUTION

Approved

Jun 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

PLERIXAFOR (plerixafor) by Hetero is cxcr4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (sdf-1α). Approved for combination with filgrastim to mobilize hematopoietic stem cells (hscs) to the peripheral blood for collection, subsequent autologous transplantation in patients with non-hodgkin's lymphoma, multiple myeloma. First approved in 2025.

Drug data last refreshed 21h ago

Mechanism of Action

CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to…

Pharmacologic Class:

Hematopoietic Stem Cell Mobilizer

Indications (3)

combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection

Worked on PLERIXAFOR at Hetero? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT05411575Phase 2Withdrawn

Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)

Started Jul 2022

COVID-19 Acute Respiratory Distress SyndromeCOVID-19

NCT05445128Phase 2Terminated

Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Started Jun 2022

1 enrolled

Sickle Cell Disease

NCT05087212Phase 4Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Started Oct 2021

53 enrolled

Autologous Haematopoietic Stem Cell Transplant

NCT04177810Phase 2Completed

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Started Nov 2020

25 enrolled

Metastatic Pancreatic Cancer

NCT03746080Phase 2Completed

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Started Dec 2018

21 enrolled

GlioblastomaGlioblastoma With Primitive Neuronal ComponentGliosarcoma+2 more